Pharmaceutical Digital Engagement Will Unlock Future Value

AN

AnalystConsensusTarget

AnalystConsensusTarget

Not Invested

Based on Analyst Price Targets

Published

08 Apr 25

Updated

09 Dec 25

n/a

n/a

AnalystConsensusTarget's Fair Value

n/a

1Y

184.6%

7D

-4.2%

Loading

1Y

184.6%

7D

-4.2%

You can edit this narrative until Dec 10 11:15 PM. Then, changes will post as Updates.

Author's Valuation

US$24.3342.3% undervalued

AnalystConsensusTarget Fair Value

Shared on 09 Dec 25

OPRX: Recurring Revenue Shift And 2026 Guidance Will Drive Future Upside

Analysts have nudged their price targets on OptimizeRx higher, with recent increases across the Street ranging from about $1 to $10 per share to reflect stronger than expected Q3 revenue and EPS, improved visibility, and confidence in sustained double digit growth and margin expansion. Analyst Commentary Bullish analysts highlighted that the latest quarter materially exceeded revenue expectations, driving meaningful EPS upside and reinforcing confidence in a durable, double digit growth profile.

Shared on 25 Nov 25

Fair value Increased 11%

OPRX: Multi-Year Guidance and Recurring Revenue Will Drive Upside Momentum

OptimizeRx's analyst price target has increased from $22 to approximately $24.33 per share. This reflects ongoing revenue outperformance and improved visibility that analysts attribute to strong quarterly results and the company's growing momentum.

Shared on 08 Nov 25

Fair value Increased 16%

OPRX: Expanding Margins and Subscription Model Will Drive Shareholder Value Forward

OptimizeRx's analyst fair value target has been raised from $19 to $22.00 per share. This change reflects stronger quarterly results, improved growth prospects, and expanding profit margins, according to analysts.

Shared on 15 Aug 25

Despite near-term cautious revenue guidance, analysts remain optimistic on OptimizeRx due to Q2 earnings outperformance, improved management transparency, and ongoing strategic initiatives, maintaining the consensus price target at $19.00. Analyst Commentary Bullish analysts highlight OptimizeRx’s Q2 revenues and adjusted EBITDA significantly surpassing forecasts.

Shared on 01 May 25

Fair value Increased 81%

Shared on 24 Apr 25

Fair value Decreased 33%

AnalystConsensusTarget made no meaningful changes to valuation assumptions.

Shared on 17 Apr 25

AnalystConsensusTarget Fair Value

US$24.33

42.3% undervalued

Future estimation in

% p.a.

0

Decrease

Increase

Current revenue growth rate

9.79%

Healthtech revenue growth rate

12.85%

Risk Level (Discount Rate)

Our default considers factors like the company's size, volatility, profitablity and country of operation.

%

0

Decrease

Increase

Current discount rate

8.50%

Calculation

US$12.03m

Earnings '28

x

49.08x

PE Ratio '28

=

US$590.24m

Market Cap '28

US$590.24m

Market Cap '28

/

19.10m

No. shares '28

=

US$30.90

Share Price '28

US$30.90 Share Price '28

Discounted to 2025 @ 8.48% p.a.

=

US$24.21

Fair Value '25